[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622938":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":146,"collaborators":11,"id":148,"slug":149,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":11,"eligibilityCriteria":154,"healthyVolunteers":150,"sex":155,"minAge":156,"maxAge":11,"enrollmentInfo":157,"targetDuration":11,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},{"fullName":5,"class":6},"Haisco Pharmaceutical Group Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR",null,[13],"Drug: Placebo",{"label":15,"type":16,"description":11,"interventionNames":17},"HSK39297 200mgQD","EXPERIMENTAL",[18],"Drug: HSK39297",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","HSK39297","HSK39297 200mg, once a day; treatment period; 48-weeks fixed dose.",[15],{"type":21,"name":9,"description":26,"armGroupLabels":27,"otherNames":11},"Placebo, once a day; treatment period; 48-weeks fixed dose.",[9],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Weifang Zeng","CONTACT","+8602867258840","zengwf@haisco.com",[35,53,63,80,91,102,113,124,135],{"facility":36,"status":37,"city":38,"state":39,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Huangshan City People's Hospital","RECRUITING","Huangshan City","Anhui","China","CN",{"type":43,"coordinates":44},"Point",[45,46],118.3125,29.71139,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},"Chao Wang","86+13851803148","wangchaoyf@haisco.com",{"facility":54,"status":37,"city":55,"state":39,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"The Second Affiliated Hospital of Wannan Medical College","Wuhu",{"type":43,"coordinates":57},[58,59],118.42947,31.35259,{"lat":59,"lon":58},[62],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},{"facility":64,"status":37,"city":65,"state":66,"zip":67,"country":40,"countryCode":41,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Peking University First Hospital","Beijing","Beijing Municipality","100034",{"type":43,"coordinates":69},[70,71],116.39723,39.9075,{"lat":71,"lon":70},[74,78],{"name":75,"role":31,"phone":76,"phoneExt":11,"email":77},"Hong Zhang, M.D.","13811123738","hongzh@bjmu.edu.cn",{"name":75,"role":79,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":81,"status":37,"city":82,"state":83,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Zhanjiang Central Hospital","Zhanjiang","Guangdong",{"type":43,"coordinates":85},[86,87],110.38749,21.23391,{"lat":87,"lon":86},[90],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},{"facility":92,"status":37,"city":93,"state":94,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Xiangya Hospital of Central South University","Changsha","Hunan",{"type":43,"coordinates":96},[97,98],112.97087,28.19874,{"lat":98,"lon":97},[101],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},{"facility":103,"status":37,"city":104,"state":105,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"The Second Hospital of Jilin University","Changchun","Jilin",{"type":43,"coordinates":107},[108,109],125.32278,43.88,{"lat":109,"lon":108},[112],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},{"facility":114,"status":37,"city":115,"state":116,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Linyi City People Hospital","Linyi","Shandong",{"type":43,"coordinates":118},[119,120],118.34278,35.06306,{"lat":120,"lon":119},[123],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},{"facility":125,"status":37,"city":126,"state":127,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine","Shanghai","Shanghai Municipality",{"type":43,"coordinates":129},[130,131],121.45806,31.22222,{"lat":131,"lon":130},[134],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},{"facility":136,"status":37,"city":137,"state":138,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Xijing Hospital","Xi’an","Shanxi",{"type":43,"coordinates":140},[141,142],113.52486,35.99785,{"lat":142,"lon":141},[145],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},{"type":147,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100622938","phase-3-phase--study-of-efficacy-and-safety-of-hsk39297-tablet-in-treatment-of-patients-with-primary-igan-100622938",false,"NCT07390123","Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN","A Randomized, Double-blind, and Placebo-controlled Parallel Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN","Inclusion Criteria:\n\n1. Subjects must have signed and dated an IRB\u002FIEC approved written informed consent form.Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study.\n2. Female and male patients above 18 years of age.\n3. Patients must weigh at least 35 kg to participate in the study, and must have a body mass index (BMI) below 35 kg\u002Fm2. BMI = Body weight (kg) \u002F \\[Height (m)\\]2\n4. Subjects with a biopsy-verified IgA nephropathy and where the biopsy was performed within the prior ten years.\n5. 24h-UPCR ≥0.75g\u002Fg or 24h-UPE≥1.0g\u002F24h at screening.\n6. Measured Glomerular Filtration Rate (GFR) or estimated GFR (using the CKD-EPI formula 2021) ≥30 mL\u002Fmin per 1.73 m2.For patients with eGFR\\* 20 to \\\u003C30ml\u002Fmin\u002F1.73m2, a qualifying biopsy performed in two years.\n\nExclusion Criteria:\n\n1. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 90 days, whichever is longer.\n2. All transplanted patients (any organ, including bone marrow).\n3. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer).\n4. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.\n5. Pregnant or nursing (lactating) women.\n6. Plasma donation (≥ 400mL) within 12 weeks prior to first dosing.","ALL","18 Years",{"count":158,"type":159},370,"ESTIMATED","INTERVENTIONAL",[162],"PHASE3","Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN",[165],"IgA Nephropathy (IgAN)","2026-05-27",{"date":168,"type":169},"2026-05-28","ACTUAL",{"date":171,"type":169},"2026-04-07",{"date":173,"type":159},"2028-07",{"name":5,"class":6},9]